Background: Since October 1999, nicardipine pellets (NP) have been used to prevent vasospasm in patients with subarachnoid hemorrhage (SAH). We started a multicenter cooperative study on Jan 1, 2007, and 136 patients in six hospitals were enrolled to this trial in 2 years. The incidence of cerebral vasospasm and outcome were examined in these patients.
Methods: The patients with SAH were treated with NP during surgery after clipping of their aneurysms.
Findings: The study included 87 female patients, 38 over 70 years old, 34 in grades 4 and 5, and 46 of Fisher group 2 or 4. Aneurysms were located on anterior circulation in 133, posterior in 3. All patients were treated with Fasudil hydrochloride except for 3. Two to twelve pellets were implanted in the cistern where thick clots existed and vasospasm was highly likely. Delayed ischemic neurological deficits (DIND), angiographical vasospasm and cerebral infarctions were seen in 11 of 134 (8.2%), 32 of 130 patients (24.6%), and 16 of 129 (12.4%), respectively. No complications were experienced. Independent rate at 3 months was 78%.
Conclusions: The incidence of cerebral vasospasm in this multicenter trial is similar to that of our first trial performed in a single center.
- Drug delivery system
- Subarachnoid hemorrhage
- Cerebral vasospasm
This is a preview of subscription content, access via your institution.
Tax calculation will be finalised at checkout
Purchases are for personal use onlyLearn about institutional subscriptions
Barth M, Capelle HH, Weidauer S, Weiss C, Münch E, Thomé C, et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome following severe aneurysmal subarachnoid hemorrhage – a prospective, randomized, double-blinded phase IIa study. Stroke 2007;38:330–336.
Drake CG. Report of world federation of neurological surgeons committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg. 1988;68:985–986.
Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6:1–9.
Jennett B, Bond M. Assessment of outcome after severe brain damage: a practical scale. Lancet 1975;1:480–484.
Kasuya H, Onda H, Takeshita M, Okada Y, Hori T. Efficacy and safety of nicardipine prolonged-release implants for preventing vasospasm in humans. Stroke 2002;33:1011–1015.
Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T. Application of nicardipine prolonged-release implants: Analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery 2005;56:895–905.
Kasuya H, Onda H, Krischek B, Hori T. Cerebral vasospasm following subarachnoid hemorrhage is completely prevented by L-type calcium channel antagonist in human. Acta Neurochir Suppl. 2008;104:109–112.
Keyrouz SG, Diringer MN. Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 2007;11:220
Krischek B, Kasuya H, Onda H, Hori H. Clinical trial of nicardipine prolonged-release implants for preventing vasospasm: Analysis of 100 consecutive patients. Neurol Med Chir (Tokyo). 2007;47:389–396.
This work was supported in part by a grant-in-aid for scientific research (C) from the Japanese Ministry of Education, Culture, Sports, Science, and Technology.
Conflict of interest statement We declare that we have no conflict of interest.
Editors and Affiliations
© 2011 Springer-Verlag/Wien
About this paper
Cite this paper
Kasuya, H. (2011). Clinical Trial of Nicardipine Prolonged-Release Implants for Preventing Cerebral Vasospasm: Multicenter Cooperative Study in Tokyo. In: Feng, H., Mao, Y., Zhang, J.H. (eds) Early Brain Injury or Cerebral Vasospasm. Acta Neurochirurgica Supplements, vol 110/2. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0356-2_30
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0355-5
Online ISBN: 978-3-7091-0356-2